Spero Therapeutics, Inc. (SPRO)
After hours:
- GlobeNewswire
Spero Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference
CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat and be available for one-on-one me
- Simply Wall St.
Spero Therapeutics Third Quarter 2022 Earnings: Misses Expectations
Spero Therapeutics ( NASDAQ:SPRO ) Third Quarter 2022 Results Key Financial Results Revenue: US$2.01m (down 35% from 3Q...
- Zacks
Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Misses Revenue Estimates
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 2.94% and 70.28%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
